Tango Therapeutics, Inc.
TNGX
Rang in aandelen
#4495
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Aandeelprijs
$27.18
Laatst gesynchroniseerd: 2026-07-31
Marktkapitalisatie
$3.38B
Verandering (1 dag)
-1.41%
Verandering (1 jaar)
213.86%
Land
US
Handel Tango Therapeutics, Inc. (TNGX)
Categorie
Healthcare
Koersgeschiedenis voor Tango Therapeutics, Inc. (TNGX)
Hoogste slotkoers: $28.53 op 2026-07-01
Laagste slotkoers: $10.21 op 2020-09-01
Laagste slotkoers: $10.21 op 2020-09-01
Koersgeschiedenis van Tango Therapeutics, Inc. van 2020 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2026 (TTM) | 94.33% |
| 2025 | 186.22% |
| 2024 | -66.61% |
| 2023 | 25.09% |
| 2022 | -28.88% |
| 2021 | -3.27% |
| 2020 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $535.81 | 25.65% |
US
|
|
| $188.41 | 601.69% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $890.95 | 9.43% |
NL
|
